e-learning
resources
Virtual 2020
Pre-Congress Content
Experimental and laboratory studies in intensive care unit medicine
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Nonsteroid anti-inflammatory agents depress inflammation-related respiratory disoders and hypoxia-induced mortality. Experimental model.
Z. Donina (St. Petersburg, Russian Federation)
Source:
Virtual Congress 2020 – Experimental and laboratory studies in intensive care unit medicine
Session:
Experimental and laboratory studies in intensive care unit medicine
Session type:
E-poster session
Number:
2758
Disease area:
Respiratory critical care
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Z. Donina (St. Petersburg, Russian Federation). Nonsteroid anti-inflammatory agents depress inflammation-related respiratory disoders and hypoxia-induced mortality. Experimental model.. 2758
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Neu-164, a novel antioxidant and anti-inflammatory compound reduces lung inflammation in a murine model of allergic asthma
Source: Annual Congress 2008 - Comorbid cardiovascular condition and therapy of asthma
Year: 2008
The anti-inflammatory effects of helminth-derived peptides in a model of endotoxin-induced acute lung injury
Source: Virtual Congress 2021 – Environmental and lifestyle impacts on chronic lung disease
Year: 2021
Ovalbumin-induced asthma model in Brown Norway rats demonstrates potential anti-asthmatic effects of Neu-164, a novel antioxidant and anti-inflammatory compound
Source: Annual Congress 2008 - Understanding allergic airway inflammation with the help of animal models
Year: 2008
Mechanisms of vascular endothelial cell injury in response to intermittent and continuous hypoxia exposure and protective effects of anti-inflammatory and anti-oxidant agents
Source: International Congress 2019 – Novel methods, diagnostics and biomarkers in chronic lung diseases
Year: 2019
Macrolide effects on the prevention of COPD exacerbations
Source: Eur Respir J 2012; 40: 485-494
Year: 2012
An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013
The anti-inflammatory effects of eucalyptol in a mouse model of LPS-induced pulmonary inflammation are mediated by TRPM8
Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models
Year: 2016
The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
The anti-inflammatory effects of PF03715455 and roflumilast on both cellular and tissue inflammation in a mouse model of COPD
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
Local and systemic imbalance of pro- and antiinflammatory cytokines in COPD
Source: Annual Congress 2009 - Airway inflammation and host defence
Year: 2009
Exploitation of anti-inflammatory mechanisms for the treatment of severe asthma
Source: Annual Congress 2005 - Mechanisms of resolution of inflammation
Year: 2005
Anti-inflammatory effect of hypoxic signaling suppression in the severe COPD model.
Source: International Congress 2018 – COPD: novel pathological mechanisms in the airway epithelium
Year: 2018
Neu-164, a novel antioxidant and anti-inflammatory compound, reduces cigarette smoke-induced lung inflammation
Source: Annual Congress 2008 - COPD
Year: 2008
Monitoring anti-inflammatory treatments in IPF and related disorders
Source: Annual Congress 2004 - Pathobiological methodologies in monitoring immunomodulatory treatments
Year: 2004
The mechanisms of antiinflammatory effect of mucolytic therapy
Source: International Congress 2014 – Predictors
Year: 2014
Mucolytics and anti-inflammatory lung treatments
Source: ERS course 2015
Year: 2015
Differential effects of simvastatin and dexamethasone on TLR3-induced anti-viral cytokines in asthmatic epithelium
Source: Annual Congress 2013 –Studies of asthma in man
Year: 2013
Rosuvastatin effects on systemic inflammation, oxidative stress and antioxidants in patients with chronic obstructive pulmonary disease
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept